Kadence Edelblut
Medical · Norton Shores, MINPI 1306486881
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 538 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 46 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 538 payments — averaging $14.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$604
- Boehringer Ingelheim$435
- AstraZeneca$420
- Amgen$363
- Novo Nordisk$322
- plus $4K from 40 others
What the payments were for
- Food & beverage$7,886100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,886 in reported general payments places this provider in the 90th percentile of 755 medical providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 74 | $42,310 |
| OzempicSemaglutide | 15 | $16,062 |
| XareltoRivaroxaban | 19 | $10,769 |
| Atorvastatin Calcium | 226 | $9,571 |
| EntrestoSacubitril/Valsartan | 12 | $8,673 |
| MyrbetriqMirabegron | 15 | $6,977 |
| Omeprazole | 124 | $5,171 |
| Donepezil Hcl | 79 | $4,112 |
| Pregabalin | 43 | $3,755 |
| Quetiapine Fumarate | 39 | $3,122 |
| Tamsulosin Hcl | 77 | $2,998 |
| Duloxetine Hcl | 71 | $2,990 |
| Gabapentin | 106 | $2,644 |
| ClopidogrelClopidogrel Bisulfate | 43 | $2,608 |
| Sertraline Hcl | 103 | $2,581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $254 | $42,31074 claims |
| Novo NordiskOzempic | $322 | $16,06215 claims |
| Johnson & JohnsonXarelto | $105 | $10,76919 claims |
| NovartisEntresto | $26 | $8,67312 claims |
| Astellas Pharma US IncMyrbetriq | $31 | $6,97715 claims |
| Lilly USA, LLCOlanzapine | $302 | $81417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 755 medical providers in Michigan.
Other medical in Norton Shores
- Amber ShullNorton Shores$154K
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$56K
- David WilkinsMuskegon$41K
- Mark RosenBerkley$32K
- Robert DemeesterRoyal Oak$27K
- John BrabantDetroit$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.